Hydroxyflavone metal complexes - molecular structure, antioxidant activity and biological effects

Kaempferol Binding to Zinc(II), Efficient Radical Scavenging through Increased Phenol Acidity

Zinc(II) enhances radical scavenging of the flavonoid kaempferol (Kaem) most significantly for the 1:1 Zn(II)-Kaem complex in equilibrium with the 1:2 Zn(II)-Kaem complex both with high affinity at 3-hydroxyl and 4-carboxyl coordination. In methanol/chloroform (7/3, v/v), 1:1 Zn(II)-Kaem complex reduces β-carotene radical cation, β-Car^•+, with a second-order rate constant, 1.88 × 10⁸ L·mol^-1·s^-1, while both Kaem and 1:2 Zn(II)-Kaem complex are nonreactive, as determined by laser flash photolysis. In ethanol, 1:1 Zn(II)-Kaem complex reduces the 2,2-diphenyl-1-picrylhydrazyl radical, DPPH^•, with a second-order rate constant, 2.48 × 10⁴ L·mol^-1·s^-1, 16 times and 2 times as efficient as Kaem and 1:2 Zn(II)-Kaem complex, respectively, as determined by stopped-flow spectroscopy. Density functional theory calculation results indicate significantly increased acidity of Kaem as ligand in 1:1 Zn(II)-Kaem complex other than in 1:2 Zn(II)-Kaem complex. Kaem in 1:1 Zn(II)-Kaem complex loses two protons (one from 3-hydroxyl and one from phenolic hydroxyl) forming 1:1 Zn(II)-(Kaem-2H) during binding with Zn(II), while Kaem in 1:2 Zn(II)-Kaem complex loses one proton in each ligand forming Zn(II)-(Kaem-H)₂, as confirmed by UV-vis absorption spectroscopy. Zn(II)-(Kaem-2H) is a far stronger reductant than Kaem and Zn(II)-(Kaem-H)₂ as determined by cyclic voltammetry. Significant rate increases for the 1:1 complex in both β-Car^•+ scavenging by electron transfer and DPPH^• scavenging by hydrogen atom transfer were ascribed to decreases of ionization potential and of bond dissociation energy of 4'-OH for deprotonated Zn(II)-(Kaem-2H), respectively. Increased phenol acidity of plant polyphenols by 1:1 coordination with Zn(II) may explain the unique function of Zn(II) as a biological antioxidant and may help to design nontoxic metal-based drugs derived from natural bioactive molecules.

Luteolin-mediated PI3K/AKT/Nrf2 signaling pathway ameliorates inorganic mercury-induced cardiac injury

Inorganic mercury is a toxic metal of worldwide concern, and causes serious cardiac injury. However, effective treatment for cardiac injury induced by mercuric chloride (HgCl₂) has not been fully identified. Luteolin (Lut) is a novel natural antioxidant. This study aimed to investigate the role of Lut on HgCl₂-induced cardiac injury. Male Wistar rats were randomly assigned to 4 groups, control, Lut (80 mg/kg intragastrically), HgCl₂ (80 mg/L, in drinking water), and HgCl₂ + Lut groups. The results indicated that Lut significantly ameliorated cardiac histopathological damage, oxidative stress, and apoptosis induced by HgCl₂ in the rat heart. Furthermore, Lut evidently increased levels of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and nuclear factor-erythroid-2-related factor 2 (Nrf2) and its downstream proteins, and inhibited NF-κB activation in the heart of rats treated by HgCl₂. Taken together, our findings suggest that activating PI3K/AKT/Nrf2 signaling pathway is involved in the protective effect of Lut against HgCl₂-induced cardiac damage.

Secondary Metabolites in the Green Synthesis of Metallic Nanoparticles

The ability of organisms and organic compounds to reduce metal ions and stabilize them into nanoparticles (NPs) forms the basis of green synthesis. To date, synthesis of NPs from various metal ions using a diverse array of plant extracts has been reported. However, a clear understanding of the mechanism of green synthesis of NPs is lacking. Although most studies have neglected to analyze the green-synthesized NPs (GNPs) for the presence of compounds derived from the extract, several studies have demonstrated the conjugation of sugars, secondary metabolites, and proteins in these biogenic NPs. Despite several reports on the bioactivities (antimicrobial, antioxidant, cytotoxic, catalytic, etc.) of GNPs, only a handful of studies have compared these activities with their chemically synthesized counterparts. These comparisons have demonstrated that GNPs possess better bioactivities than NPs synthesized by other methods, which might be attributed to the presence of plant-derived compounds in these NPs. The ability of NPs to bind with organic compounds to form a stable complex has huge potential in the harvesting of precious molecules and for drug discovery, if harnessed meticulously. A thorough understanding of the mechanisms of green synthesis and high-throughput screening of stabilizing/capping agents on the physico-chemical properties of GNPs is warranted to realize the full potential of green nanotechnology.

Metal Complexes of Natural Product Like-compounds with Antitumor Activity

Cancer continues to be one of the major causes of death worldwide. Despite many advances in the understanding of this complex disease, new approaches are needed to improve the efficacy of current therapeutic treatments against aggressive tumors. Natural products are one of the most consistently successful sources of drug leads. In recent decades, research activity into the clinical potential of this class of compounds in cancer has increased. Furthermore, a highly promising field is the use of metals and their complexes in the design and development of metal-based drugs for the treatment of cancer. Metal complexes offer unique opportunities due to their ability to alter pharmacology, improving the efficacy and/or reducing the negative side effects of drug molecules. In addition, transition metals as copper, iron, and manganese, among others, can interact with active sites of enzymes, playing important roles in multiple biological processes. Thus, these complexes not only possess higher activities but also reach their targets more efficiently. This review article highlights recent advances on the emerging and expanding field of metal-based drugs. The emphasis is on new therapeutic strategies consisting of metal complexes with natural product like-compounds as a starting point for the rational design of new antitumor agents.